Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers

INTRODUCTION: Immune checkpoint inhibitors (ICI) have become a primary treatment modality for patients with a variety of malignancies. Given their increasing use, it is essential to be familiar with their immune-related adverse events (irAEs). Here we report a severe case of autoimmune hemolytic ane...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Natasha A, Zhao, Songzhu, Wei, Lai, Rogers, Kerry A, Otterson, Gregory A, Wang, Tzu-Fei, Owen, Dwight H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680604/
https://www.ncbi.nlm.nih.gov/pubmed/33235503
http://dx.doi.org/10.2147/CMAR.S264166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680604/
https://www.ncbi.nlm.nih.gov/pubmed/33235503
http://dx.doi.org/10.2147/CMAR.S264166

Ejemplares similares